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Abstract
Background: Extramural tumor deposits (TDs) and extracapsular lymph node involvement (ECLNI) are considered
to be poor prognostic factors in patients with T3–4, N0–2, M0 colorectal cancer (CRC). Although TDs are known to
have multiple origins and pleomorphic features, the prognostic significances of the different type of TDs have not
yet been established.
Methods: We performed a retrospective review of 385 consecutive patients with T3–4, N0–2, M0 CRC who received
curative resection at our institution between 2006 and 2012. We classified the TDs into two groups: invasive-type
TD (iTD), which is characterized by the presence of lymphatic invasion, vascular invasion, perineural invasion, or
undefined cancer cell clusters and nodular-type TD (nTD), which is characterized by a smooth or irregular-shaped
tumor nodule other than an iTD. ECLNI was defined as invasion of cancer cells into capsular collagen tissues or
adipose tissues beyond the capsular collagen. Multivariate analyses were used to assess the prognostic significance
of iTD, ND, and ECLNI for relapse-free survival (RFS), disease-specific survival (DSS), and sites of recurrence.
Results: In patients without lymph node (LN) metastasis, the incidences of iTD and nTD were both in the range of
2–3 %. Conversely, in patients with LN metastasis, the incidences of iTD, nTD, and ECLNI were 31, 22, and 34 %,
respectively. iTD, nTD, and ECLNI were all significant independent adverse factors for RFS in rectal cancer, and were
all associated with pT, pN, and LN ratio. iTD was a significant independent adverse prognostic factor for DSS in
rectal cancer, metastasis to the liver in colorectal cancer, and distant LN metastasis in colon cancer. ECLNI was a
significant independent prognostic factor for RFS in colon cancer.
Conclusions: Classifying TDs and assessing ECLNI may help establish significant prognostic factors for patients with
T3–4, N0–2, M0 CRC.
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Background
Colorectal cancer (CRC) is one of the most common ma-
lignancies in the world. In Japan, it is the third and second
most common cancer in men and women, respectively
[1]. Although most patients are diagnosed in the early
stages of the disease (without distant metastasis or locally
advanced status), some patients develop local or distant
recurrence within 5 years of undergoing curative resec-
tion; therefore, accurate assessments of the risk of recur-
rence are important for improving the prognosis of this
disease, and the TNM staging system has been revised ac-
cordingly every several years. Of note, although the evalu-
ation of N status is especially critical for TNM staging, the
definition and significance of extramural tumor deposits
(TDs), which affect the N status, remain controversial.
Further, extracapsular lymph node involvement (ECLNI)
has not yet been adopted as a factor for staging [2].
The presence of TDs in the resected specimen is
considered to be a poor prognostic factor [3–8]. In
the 5th edition of the TNM classification manual, TDs
were originally classified according to size (larger or
smaller than 3 mm), whereas in the 6th edition, they
were further classified according to shape (smooth or
irregular) [9, 10]. In the 7th and most recent edition,
TDs are considered as an N factor (N1c) in cases of
T1–2 disease without lymph node (LN) metastasis
[11]. TDs in T1–2 disease were defined as a T factor
or an N factor in the previous versions of the TNM
classification. In the 7th and most recent edition, TDs
are considered as an N factor (N1c) in cases of T1–4
disease without lymph node (LN) metastasis [11].
However, the effect of TD status is not mentioned for
cases of T1–4 disease with LN metastasis [11]. There-
fore, we focused on TDs in T3-4 tumor disease with
or without lymph node metastasis.
Although TDs are considered to originate from the
lymphovascular/perineural invasion of cancer cells
[4, 12], the morphology of TDs is so diverse that their or-
igins are unclear in many cases [12, 13]. The most critical
problem is distinguishing TDs from LN metastasis, as the
number of LN metastases influences staging [13]. Accord-
ingly (as mentioned above), TD and LN metastasis have
been distinguished in the TNM staging systems based on
the size or shape of the lesion [9, 10], and several previous
studies have assessed the independent prognostic signifi-
cances of various TD classifications, including irregular or
smooth nodules, lymphocyte invasion, vascular invasion,
and aggressive patterns [5–8].
Moreover, some previous studies have also reported
that ECLNI is an adverse prognostic factor, although the
TNM system has not yet incorporated ECLNI status into
the staging [14–16]. ECLNI is defined as an invasive
cancer aggregate beyond the LN capsule. However,
Brabender et al. reported on ECLNI comprising TDs
without perineural invasion or vessel involvement, sug-
gesting that it is necessary to distinguish between TDs
and ECLNI [16].
Considering the issues mentioned above, we under-
took the present study to assess the prognostic signifi-
cance of TD types and ECLNI status in patients with
T3–4, N0–2, M0 CRC. For the purposes of our study,
TDs were classified into two types: invasive-type tumor
deposits (iTDs), which refer to cancer aggregates with
lymphovascular or perineural invasion, or clusters of
cancer cells and nodule-type tumor deposits (nTD),
which refer to other TDs. In this manner, we have classi-
fied TDs according to whether their origins are clear, ra-
ther than their sizes and shapes.
Methods
Patients
We conducted a pathological and clinical review of 385
consecutive patients with T3 (327 patients) or T4 (58 pa-
tients) plus N0 (206 patients), N1 (125 patients), or N2
(54 patients) status who received curative resection for
colon (289 patients) or rectal (96 patients) cancer at our
hospital between 2006 and 2012. This study was approved
by the ethics committee of Hyogo College of Medicine.
Written informed consent was obtained from all included
patients. We excluded patients with CRC who met any of
the following criteria: inflammatory bowel disease, such as
ulcerative colitis or Crohn’s disease; familial adenomatous
polyposis; a history of any other advanced cancer within
the 5 years prior to the diagnosis of CRC; preoperative
chemotherapy and/or radiation therapy for CRC. The clin-
ical data collected included the patient demographics, the
operation performed, adjuvant chemotherapy, and out-
patient follow-up information on recurrence and survival.
Relapse-free survival (RFS) was defined as the interval (in
months) between the date of surgical removal of the pri-
mary tumor and the date at which relapse was confirmed
or the date of the last follow-up (for censored patients).
Disease-specific survival (DSS) was defined as the interval
(in months) between the date of surgical removal of the
primary tumor and the date of death from cancer or the
date of the last follow-up (for censored patients). As adju-
vant treatment after surgery, 70 of the 206 (34 %) patients
with stage II CRC, and 131 of 179 (73 %) patients with
stage III CRC received 5-fluorouracil-based chemother-
apy. Recurrence was assessed every 3–6 months based on
physical examinations, blood tests, and computed tomog-
raphy scans. The mean and median follow-up periods
were 46.9 and 46.0 months, respectively.
Pathological examination
The resected specimens were retrieved and reviewed for
routine pathological evaluation by hematoxylin and
eosin staining according to the 7th edition of the TNM
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classification [11]. The specimens that had been har-
vested for the pathological examination of LN metastasis
were further reviewed to evaluate the presence of TDs
and ECLNI. As mentioned above, TDs were classified as
either iTD (vascular invasion, lymphatic invasion, peri-
neural invasion, and undefined cancer clusters) or nTD
(cancer aggregates that had smooth or irregular shapes
without an iTD component) (Fig. 1). ECLNI was defined
as invasion of cancer cells into the capsular collagen tis-
sues or into the adipose tissues beyond the capsular col-
lagen (Fig. 1) [14]. The presence and definitions of iTDs,
nTDs, and ECLNI were determined by a pathologist
(S.S.) who was blinded to the patients’ clinical data.
Statistical analyses
Clinicopathological differences between patients with
and without iTDs, nTDs, or ECLNI were assessed
using Fisher’s exact test, the χ2 test, or Student’s t
test, as appropriate. Survival was analyzed using the
Kaplan–Meier method, and stratified according to the
various clinicopathological features. Significant differences
between the survival curves were verified by the Log-rank
test. Multivariate survival analyses were performed using
Cox proportional hazards regression. All analyses were
performed using Jump software (version 11; SAS Japan
Corp., Tokyo, Japan).
Results
TD type (iTD vs. nTD) and clinicopathological features
First, we evaluated the effects of iTD/nTD status on clini-
copathological features. Overall, iTDs and nTDs were
present in 16 and 12 % of patients, respectively. Among
LN-positive patients, the corresponding rates were 31 and
22 %, respectively, whereas among LN-negative patients,
the corresponding rates were only 2–3 %. Significant differ-
ences were observed between iTD(+) and iTD(−) patients
in terms of several clinicopathological features, including
pT, pN, LN ratio, lymphatic invasion, venous invasion,
nTD, ECLNI, and adjuvant chemotherapy, as well as recur-
rence and cancer-specific death (Table 1). Considering pa-
tients who developed recurrence, there was a higher
proportion of M1b cases than M1a cases among iTD(+)
patients, as compared with iTD(−) patients. No differences
were observed between nTD(+) and nTD(−) patients with
regard to most clinicopathological features, except for
tumor site, M status, and cancer-specific death (Table 1).
Fig. 1 Schematic illustrations and photos. a Lymph node (LN) metastasis. b, d-f Extramural tumor deposits (TDs). c, i, g Extracapsular lymph node
involvement (ECLNI). TD was classified as invasive type (iTD) (d, e) or nodular type (nTD) (f) in this study
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Table 1 Associations between iTD, nTD, and ECLNI status and various clinicopathological features
iTD nTD ECLNI
Features (+) (n = 60) (−) (n = 325) P-value (+) (n = 45) (−) (n = 340) P-value (+) (n = 60) (−) (n = 119) P-value
Age (years)
Mean 67.1 67.7 0.67 65.6 67.9 0.19 68.3 66.2 0.22
Range 26–89 33–91 26–89 33–91 48–89 26–88
≥ 70 27 150 0.89 18 159 0.43 25 54 0.75
< 70 33 175 27 181 35 65
Gender 0.26 0.75 0.75
Male 39 183 25 197 34 64
Female 21 142 20 143 26 55
CEA (ng/ml) 0.56 0.75 0.50
>5 22 127 20 129 26 44
≤5 34 164 24 174 29 64
Tumor site 0.20 0.0028 0.036
Colon 41 248 25 264 49 78
Rectum 19 77 20 76 11 41
Tumor size (cm) 0.82 1.0 1.0
<5 27 144 20 151 29 57
≥5 33 181 25 189 31 62
Histology 1.0 0.26 1.0
Well/moderate 55 296 39 312 54 106
Others 5 29 6 28 6 13
pT 0.0050 0.027 0.02
3 43 284 33 294 41 100
4 17 41 12 46 19 19
LNs (n) 0.65 0.17 0.49
≥12 40 226 27 239 45 82
<12 20 99 18 101 15 37
pN <0.0001 <0.0001 <0.0001
0 5 201 6 200 – –
1 28 97 21 104 30 95
2 27 27 18 36 30 24
LN ratio <0.0001 <0.0001 0.0027
≥0.29 26 17 17 26 23 20
<0.29 34 308 28 314 37 99
Lymphatic invasion 0.0015 0.039 0.49
(+) 53 230 39 244 49 99
(−) 5 87 5 87 10 14
Venous invasion 0.026 0.0069 0.27
(+) 55 263 43 275 56 100
(−) 3 53 1 55 3 13
Stage <0.0001 <0.0001
II 5 201 6 200
III 55 124 39 140 60 119
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To clarify the prognostic differences between iTD and
nTD, we assessed RFS and DSS according to both TD
status and node positivity. TD status was classified into
the following categories: iTD alone, nTD alone, both
iTD and nTD (iTD(+)/nTD(+)), and no TD (TD(−)). On
comparing iTD(+)/nTD(+) and TD(−) groups of node-
negative patients, we observed significant differences in
both the RFS and DSS rates (P = 0.038 and 0.018, re-
spectively, Fig. 2a and b). Among node-positive patients,
the RFS rates differed significantly between iTD(+)/
nTD(+) and nTD alone groups, between iTD(+)/nTD(+)
and TD(−) groups, and between iTD alone and TD(−)
groups (Fig. 2c). Further, among node-positive patients,
the DSS rates differed significantly between iTD alone
group and both TD(−) group and nTD alone group
(Fig. 2d). These findings indicated the importance of TD
classification for the evaluation of prognosis.
ECLNI status and clinicopathological features
The incidence of ECLNI was 34 % in patients with
T3–4, N1–2 disease. The presence of ECLNI was signifi-
cantly related to numerous clinicopathological features,
including tumor site, pT, pN, LN ratio, iTD, adjuvant
chemotherapy, and recurrence. However, the presence of
ECLNI was not related to lymphatic invasion, venous in-
vasion, or cancer-specific death (Table 1). Moreover,
ECLNI status was significantly related to iTD, but not to
nTD (Table 1).
Comparison of TD and ECLNI in terms of RFS
To compare the associations of TD and ECLNI with
prognosis, we investigated RFS according to TD status,
ECLNI status, and cancer type (colon vs. rectum) in pa-
tients with LN metastasis. TD status and ECLNI status
were classified as follows: TD alone, ECLNI alone, nei-
ther TD nor ECLNI (TD(−)/ECLNI(−)), and both TD
and ECLNI (TD(+)/ECLNI(+)). Among patients with
colon cancer, the RFS rates of TD(+)/ECLNI(+) group
differed significantly from those of TD alone, ECLNI
alone, and TD(−)/ECLNI(−) groups (Fig. 2e). Further,
among patients with rectal cancer, the RFS rates of
TD(−)/ECLNI(−) group differed significantly from those
of TD alone and ECLNI alone groups.
These results indicated that TD and ECLNI had differ-
ent prognostic associations for colon cancer and rectal
cancer. The presence of both TD and ECLNI was associ-
ated with poorer RFS in colon cancer. On the other
hand, presence of either TD or ECLNI was associated
with poorer RFS in rectal cancer.
Univariate and multivariate analyses of factors associated
with RFS and DSS
To evaluate the prognostic significance of iTD, nTD,
and ECLNI for RFS and DSS, univariate analyses were
performed (Log-rank test) for a total of 15 clinicopatho-
logical factors, including factors that have been assessed
by previous reports (Table 2). Four factors (pN, LN ratio,
Table 1 Associations between iTD, nTD, and ECLNI status and various clinicopathological features (Continued)
Chemotherapy 0.003 0.0008 0.033
(+) 42 159 34 167 50 81
(−) 18 166 11 173 10 38
Recurrence <0.0001 <0.0001 0.032
(−) 29 273 23 279 32 87
(+) Ma 3 23 8 18 8 9 1.0
(+) Mb 28 29 0.0012 14 43 0.60 20 23
Cancer-specific death 0.0001 0.26 1.0
(+) 10 10 4 15 5 9
(−) 50 315 41 325 55 110
nTD <0.0001 0.34
(+) 21 24 – – 16 23
(−) 39 301 – – 44 96
ECLNI <0.0001 0.0003
(+) 25 35 16 44 – –
(−) 35 290 29 296 – –
iTD <0.0001 0.027
(+) – – 21 39 25 32
(−) – – 24 301 35 87
iTD invasive-type tumor deposits, nTD nodular-type tumor deposits, ECLNI extracapsular lymph node involvement, CEA carcinoembryonic antigen, LN lymph node
Bold text indicates statistically significant P-values (<0.05)
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Fig. 2 Kaplan–Meier survival curves for patients depending on TD status and ECLNI status. We analyzed associations between survival and the presence
of invasive-type tumor deposits (iTDs), nodular-type tumor deposits (nTDs), and extracapsular lymph node involvement (ECLNI). These analyses were
further stratified according to N status. a Among node-negative patients, relapse-free survival (RFS) differed significantly between the both iTD and nTD
(iTD(+)/nTD(+)) and no TD (TD(−)) groups (P = 0.038). b Among node-negative patients, disease-specific survival (DSS) differed significantly between the
iTD(+)/nTD(+) and TD(−) groups (P= 0.018). c Among node-positive patients, the RFS rates of the iTD(+)/nTD(+) group differed significantly from those
of the TD(−) group and the nTD alone group (P = 0.0001 and 0.041, respectively). Among node-positive patients, RFS differed significantly between the
iTD alone and TD(−) in groups (P = 0.021). d Among node-positive patients, the DSS rates of the iTD alone group differed significantly from those of the
TD(−) group and the nTD alone group (P = 0.016 and 0.013, respectively). e Among node-positive patients with colon cancer, the RFS rates of the
TD(+)/ECLNI(+) group differed significantly from those of the TD(−)/ECLNI(−), TD alone, and ECLNI alone groups (P= 0.002, 0.012, and 0.049, respectively).
f Among node-positive patients with rectal cancer, the RFS rates of the TD(−)/ECLNI(−) group differed significantly from those of the TD alone group and
the ECLNI alone group (P= 0.0051 and 0.022, respectively)
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iTD, and nTD) were found to be significantly related to
RFS in both colon and rectal cancer. Five factors (pT,
total LN count, lymphatic invasion, venous invasion, and
ECLNI) were found to be significantly related to RFS in
either colon or rectal cancer. Three factors (pT, pN, and
iTD) were significantly associated with both DSS and
RFS in colon cancer. Finally, 2 factors (LN ratio and
iTD) were significantly associated with both DSS and
RFS in rectal cancer.
Multivariate analyses were performed, including factors
that had been found to have associations with P < 0.1 in
univariate analysis. The multivariate analyses revealed that
ECLNI was significantly and independently associated
with RFS in colon and rectal cancer, while iTD and nTD
were significantly and independently associated with RFS
in rectal cancer alone. Further, the multivariate analyses
showed that pT was significantly and independently asso-
ciated with DSS in colon cancer, while iTD was signifi-
cantly and independently associated with DSS in rectal
cancer (Table 2).
Univariate and multivariate analyses of factors associated
with the site of recurrence
Additional univariate and multivariate analyses were
performed to identify factors associated with the sites
of recurrence (Table 3). Using univariate analyses, we
investigated the associations between 15 clinicopatho-
logical factors and liver metastasis, lung metastasis,
and distant LN metastasis. All factors with P < 0.1 were
further included in multivariate analyses. Of iTD, nTD,
and ECLNI status, iTD was found to be an independent
factor for liver and distant LN metastasis in colon cancer
and nTD was found to be an independent factor for liver
metastasis in colon cancer. We identified no independent
factor for lung metastasis in colon and rectal cancer.
Discussion and conclusions
Here, we have evaluated the usefulness of cancer lesions
(other than typical LN metastases in soft tissues) for
assessing the prognosis of patients with CRC. These can-
cer lesions included TDs, which were further classified
into iTDs and nTDs, and ECLNI (Fig. 1). We found that
these factors were significantly prognostic for patients
with T3–4, N0–2, M0 disease.
The presence of TDs has previously been reported as
a significant prognostic factor in CRC patients receiving
curative resection, and TD status has been adopted as
part of both the current (7th edition) and previous (5th
and 6th editions) TNM staging systems [9–11]. However,
the definition of TDs remains controversial, and it has
changed in every revision of the TNM staging system
since its first inclusion [2, 3, 9–11]. Rock et al. further
reported that the diagnosis of TDs varied among pathol-
ogists, indicating the need for a distinct definition of
TDs [13]. TDs have been reported to contain many types
of cancer cells that differ in size, shape, and origin.
Table 2 Univariate and multivariate analyses of factors associated with RFS and DSS
Colon Rectum
Factor RFS DSS RFS DSS
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
P P P P
Age (years): ≥70 0.75 – 0.59 – 0.23 – 0.045 0.70
Gender: male 0.47 – 0.68 – 0.35 – 0.22 –
CEA (ng/ml): >5 0.50 – 0.69 – 0.24 – 0.34 –
pT: 3 vs. 4 0.0029 0.66 <0.0001 0.0026 0.33 – 0.14 –
Tumor size (cm): <5 0.49 – 0.46 – 0.054 0.47 0.75 –
Histology: well/moderate 0.71 – 0.49 – 0.51 – 0.48 –
pN: (+) 0.0005 0.84 0.021 0.47 <0.0001 0.079 0.22 –
Total LNs count: <12 0.41 – 0.95 – 0.03 0.062 0.23 –
LN ratio: >0.29 <0.0001 0.73 0.40 <0.0001 0.65 0.026 0.67
Lymphatic invasion: (+) 0.23 – 0.51 – 0.045 0.36 0.38 –
Venous invasion: (+) 0.034 0.14 0.13 – 0.18 – 0.24 –
Chemotherapy: (−) 0.13 – 0.031 0.35 0.53 – 0.39 –
iTD: (+) <0.0001 0.052 0.0038 0.32 <0.0001 0.0039 <0.0001 0.021
nTD: (+) <0.0001 0.075 0.26 – 0.017 0.047 0.65 –
ECLNI: (+) 0.0013 0.02 0.22 – 0.093 0.025 0.31 –
RFS relapse-free survival, DSS disease-specific survival, CEA carcinoembryonic antigen, LN lymph node, iTD invasive-type tumor deposits, nTD nodular-type tumor
deposits, ECLNI extracapsular lymph node invasion
Bold text indicates statistically significant P-values (<0.05)
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Although classifications of TDs have been developed,
the value of these different classifications has not yet
been established, largely because the classification of
TDs is difficult [5–8]. Here, we simply classified TDs
into two types: iTD, which was defined by vascular/
lymphatic/perineural invasion, and nTD, which refers to
other TDs. To the best of our knowledge, our report is
the first to i) show the prognostic significance of classi-
fied TDs in specimens that were resected to assess LN
metastasis and ii) include a multivariate analysis adjusted
for several factors, including TDs and ECLNI.
ECLNI has not yet been adopted in the TNM staging
system, even though its prognostic significance has been
reported in several gastrointestinal malignancies, includ-
ing esophageal cancer, gastric cancer, and CRC [17]. The
definition of ECLNI appears to be clearer than that of
TD, although the prevalence of ECLNI varies across the
available reports [5, 14–16]. Of note, TD and ECLNI sta-
tus have rarely been assessed together, even though it
seems necessary to distinguish between ECLNI and TDs
near LN metastases [5, 15] (Fig. 1). Puppa et al. demon-
strated that TD status—but not ECLNI status—was sig-
nificantly associated with disease-free survival (DFS) and
overall survival in their multivariate analyses [5]. Al-
though Puppa et al. assessed DFS and overall survival,
we assessed RFS and DSS in order to exclude second
malignancies and deaths unrelated to cancer. On the
other hand, Wind et al. found that ECLNI status—but
not TD status—was a significant predictor of DFS in
stage III colon cancer [15]. These different findings seem
to result from the different pathological diagnoses of TD
and ECLNI. Unlike these previous studies, the present
study includes adjustments for several prognostic fac-
tors, such as preoperative carcinoembryonic antigen, pT,
tumor site (colon or rectum), and TD types (iTD and
nTD). Our results demonstrated that TD types and
ECLNI were more potent prognostic factors than node
positivity or LN ratio >0.29, which have been considered
to be some of the strongest predictors of survival. In a
multivariate analysis that excluded iTD, nTD, and
ECLNI status, we found that pN (+) was a significant
and independent factor for RFS rates of patients with
colon (P = 0.034) and rectal (P = 0.0011) cancers. There-
fore, node positivity seemed less powerful than iTD,
nTD, or ECLNI as a predictor of survival in this study.
Further, our results appear compatible with those of pre-
vious reports, both in the sense that vascular invasion,
lymphatic invasion, and perineural invasion of cancer
cells seemed to be the origins of TDs [5, 12,], and in
terms of the poor prognostic outcomes that were associ-
ated with TDs [6, 7].
It is likely that the presence of iTD in soft tissues indi-
cates the movement of cancer cells from the primary site
to distant metastatic sites through the vascular, lymph-
atic, and/or perineural routes. In this sense, assessments
of iTD status appear to be more useful than assessments
Table 3 Univariate and multivariate analyses of factors associated with the sites of recurrence
Colon Rectum
Liver Lung Distant LN Liver Lung Distant LN
P P P P P P
Factor Uni Multi Uni Multi Uni Multi Uni Multi Uni Multi Uni Multi
Age (years): ≥70 0.55 – 0.20 – 0.054 0.15 0.057 – 0.74 – 0.64 –
Gender: Male 0.27 – 0.10 – 0.025 0.041 0.41 – 0.94 – 0.70 –
CEA (ng/ml): >5 0.14 – 0.26 – 0.54 – 0.78 – 0.59 – 0.75 –
pT: 4 0.016 0.88 0.51 – 0.0097 0.76 0.65 – 0.93 – 0.092 0.32
Tumor size (cm): <5 0.88 – 0.58 – 0.60 – 0.099 – 0.02 0.14 0.11 –
Histology: well/moderate 0.46 – 0.29 – 0.72 – 0.63 – 0.75 – 0.51 –
pN: (+) 0.0003 0.70 0.057 0.51 0.0006 0.64 0.023 0.22 0.0003 0.078 0.0097 0.55
Total LNs count: <12 0.41 – 0.17 – 0.43 – 0.099 – 0.064 0.16 0.36 –
LN ratio: ≥0.29 0.0013 0.99 0.098 0.49 0.0002 0.92 0.076 – <0.0001 0.20 0.0041 0.44
Lymphatic invasion: (+) 0.033 0.37 0.50 – 0.28 – 0.13 – 0.023 0.48 0.015 0.13
Venous invasion: (+) 0.029 0.37 0.090 0.18 0.065 0.49 0.84 – 0.28 – 0.066 0,28
Chemotherapy: (−) 0.11 – 0.46 – 0.0003 0.18 0.82 – 0.30 – 0.083 0.29
iTD: (+) <0.0001 0.013 0.80 – <0.0001 0.0055 0.011 0.0032 0.0008 0.27 0.029 0.59
nTD: (+) <0.0001 0.010 0.50 – 0.0026 0.15 0.70 – 0.12 – 0.94 –
ECLNI: (+) 0.0004 0.22 0.04 0.27 <0.0001 0.078 0.027 0.20 0.03 0.45 0.022 0.16
RFS relapse-free survival, DSS disease-specific survival, CI confidence interval, CEA carcinoembryonic antigen, LN lymph node, iTD invasive-type tumor deposits,
nTD nodular-type tumor deposits, ECLNI extracapsular lymph node involvement. Uni univariate analysis, Multi multivariate analysis
Bold text indicates statistically significant P-values (<0.05). Underlined text indicates factors that were statistically significant in multivariate analysis
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of vascular invasion, lymphatic invasion, or perineural in-
vasion in the primary tumor, which have previously been
recognized as negative prognostic factors [18]. It is likely
that the origins of nTD and ECLNI are also vascular inva-
sion, lymphatic invasion, or perineural invasion of cancer
cells, because these factors are associated with RFS.
In the present study, metastasis to the liver was fre-
quent among iTD(+) patients with colon or rectal cancer
and nTD(+) patients with colon cancer, whereas metas-
tasis to the lung was not. Metastasis to the distant LNs
was also frequent in iTD(+) patients with colon cancer.
This finding indicates that cancer cells recognized as
iTDs likely metastasize to the liver through the portal
vein system, and subsequently metastasize to the distant
LNs from liver in colon cancer, but not in rectal cancer.
In contrast, lung metastasis is established by systems
that differ from those used by iTD or nTD. The high fre-
quency of metastasis to the distant LNs in patients with
TDs is similar to the findings of a previous report [4].
There were some limitations to our work. Most import-
antly, this is a single-center study and pathological diagno-
sis was performed by a single pathologist. Multi-center
studies should be performed to confirm our findings, and
objective tools are indispensable for the definition and
diagnosis of TDs. Thus, identifying molecular markers as-
sociated with the presence of TDs and ECLNI will aid in
understanding the mechanisms of cancer metastasis.
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